Femasys (FEMY)
(Delayed Data from NSDQ)
$1.20 USD
+0.08 (7.14%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $1.18 -0.02 (-1.67%) 4:36 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Price, Consensus and EPS Surprise
FEMY 1.20 +0.08(7.14%)
Will FEMY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for FEMY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FEMY
Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates
IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
FEMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know
Femasys (FEMY) to Report Q3 Earnings: What's in the Cards?
Other News for FEMY
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
12 Health Care Stocks Moving In Thursday's Intraday Session
Gold Rises 1%; Accenture Shares Surge After Q3 Results
Femasys Set for Growth: Buy Rating Backed by EU Regulatory Success and Strategic U.S. Expansion